InsiderPulseNo transactions found.
| Metric | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Amortization and depreciation | $128K-56.7% | $295K+10791.2% | $3K-97.9% | $129K |
| General and administrative | $704K-68.4% | $2.2M+161.1% | $853K-60.3% | $2.1M |
| Payroll and consulting fees | $412K-79.2% | $2.0M+934.2% | $191K | — |
| Professional fees | $335K-33.9% | $507K-57.5% | $1.2M+27.9% | $933K |
| Rent | $3K-78.9% | $12K | $0-100.0% | $36K |
| Stock-based compensation | $0-100.0% | $181K-50.2% | $363K-55.7% | $820K |
| Travel and entertainment | $0-100.0% | $11K-24.2% | $14K | — |
| Total operating expenses | $1.6M-69.7% | $5.2M+74.1% | $3.0M-79.3% | $14.5M |
| Loss from operations | -$1.6M+69.7% | -$5.2M-74.1% | -$3.0M+79.3% | -$14.5M |
| Change in the fair value of derivative liability | -$256K+49.0% | -$501K-115.8% | $3.2M+186.2% | -$3.7M |
| Change in the fair value of obligation to issue shares | $402K | $0 | — | — |
| Interest expense | -$1.7M+26.2% | -$2.3M-51.9% | -$1.5M+34.3% | -$2.3M |
| Loss on the extinguishment of debt | -$655K+29.6% | -$930K+36.0% | -$1.5M-356.5% | $566K |
| Loss on impairment of investment | -$79K | $0+100.0% | -$6.7M | $0 |
| Other income | $0-100.0% | $402K | $0 | — |
| Gain on loan dissolution | $7.5M | $0 | — | — |
| Total other income (expenses), net | $5.3M+258.8% | -$3.3M+43.2% | -$5.8M-8.1% | -$5.4M |
| Net income (loss) | $3.7M+143.2% | -$8.5M+3.4% | -$8.8M+55.6% | -$19.9M |
| Foreign currency translation adjustment | -$276K-145.1% | $612K+2437.6% | -$26K+94.6% | -$483K |
| Net comprehensive loss | $3.4M+143.1% | -$7.9M+10.6% | -$8.9M+56.5% | -$20.4M |
| Basic loss per common share | $0.01+125.0% | -$0.04 | — | — |
| Diluted loss per common share | $0.01+125.0% | -$0.04 | — | — |
| Weighted average number of shares outstanding, Basic | $308.9M+46.4% | $211.0M | — | $40.7M |
| Weighted average number of shares outstanding, Diluted | $308.9M+46.4% | $211.0M | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026
CannaPharmaRX Expands Cannabis Exports, Projects $1M+ Q3 Revenue
CannapharmaRx pays off convertible notes
CannaPharmaRx, Nasha ink pact for cannabis strains